H.C. Wainwright lowered the firm’s price target on Puma Biotechnology to $7 from $8 and keeps a Buy rating on the shares, citing a lower 2025 non-GAAP EPS estimate of 70c after the company reported Q4 U.S. Nerlynx sales that were negatively impacted by lower enrollments seen in Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PBYI: